Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT00943592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00943592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Lead sponsor
University of Chicago
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2006
Completion date
November 30, 2013
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hematologic malignancies, leukemia, preleukemia